Relevance of pharmacogenomics for developing countries in Europe

Drug Metabolism and Drug Interactions

Volumn 26, Issue 4, 2011, Pages 143-146

  Mitropoulos, Konstantinos ^a   Johnson, Lindsey ^b   Vozikis, Athanassios ^c   Patrinos, George P ^a,d  

^a Golden Helix Institute of Biomedical Research   (Greece)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF PIRAEUS   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

allele frequencies; developing countries; marker; pharmacogenomics; single nucleotide polymorphisms

Indexed keywords

ABACAVIR; ANTIDEPRESSANT AGENT; AZATHIOPRINE; CARBAMAZEPINE; CLOPIDOGREL; CODEINE; IMATINIB; IRINOTECAN; MERCAPTOPURINE; SEROTONIN 3 ANTAGONIST; TAMOXIFEN; TRASTUZUMAB; WARFARIN;

ARTICLE; CLINICAL PRACTICE; EUROPE; GENE FREQUENCY; GENE SEQUENCE; GENETIC MARKER; GENETIC SCREENING; GENOTYPE; HEALTH CARE SYSTEM; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

DEVELOPING COUNTRIES; EUROPE; HUMANS; PHARMACOGENETICS;

EID: 83655197768     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2011.028     Document Type: Article

References (15)

1. Squassina A, Artac M, Manolopoulos VG, Karkabouna S, Lappa- Manakou C, Mitropoulos K, et al. Translation of genetic knowledge into clinical practice: the expectations and realities of pharmacogenomics and personalized medicine. Pharmacogenomics 2010;11:1149-67.
2. Roederer MW, Sanchez-Giron F, Kalideen K, Kudzi W, McLeod HL, Zhang W. The pharmacogenetics for every nation initiative. Pharmacogenetics and rational drug use around the world. Pharmacogenomics 2011;12:897-905.
3. Roederer MW, McLeod HL. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics 2010;11:633-6.
4. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity ? J HIV Ther 2003;8:36-41.
5. Georgitsi M, Viennas E, Gkantouna V, Christodoulopoulou E, Zagoriti Z, Tafrali C, et al. Population-specifi c documentation of pharmacogenomic markers and their allelic frequencies in FINDbase. Pharmacogenomics 2011;12:49-58.
6. Georgitsi M, Viennas E, Gkantouna V, van Baal S, Petricoin EF, Poulas K, et al. FINDbase: a worldwide database for genetic variation allele frequencies updated. Nucleic Acids Res 2011;39:D926-32.
7. Stojiljkovic M, Patrinos GP, Pavlovic S. Clinical applicability of sequence variations in genes related to drug metabolism. Curr Drug Metab 2011;12:445-54.
8. Marsh S, van Booven DJ, McLeod HL. Global pharmacogenetics: giving the genome to the masses. Pharmacogenomics 2006;7:625-31. (Pubitemid 43891418)
9. Giardine B, Borg J, Higgs DR, Peterson KR, Philipsen S, Maglott D, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet 2011;43:295-301.
10. Sagia A, Cooper DN, Poulas K, Stathakopoulos V, Patrinos GP. A critical appraisal of the private genetic and pharmacogenomic testing environment in Greece. Pers Med 2011;8:413-20.
11. Mai Y, Koromila T, Sagia A, Cooper DN, Vlachopoulos G, Lagoumintzis G, et al. A critical view of the general public ' s awareness and physicians ' opinion of the trends and potential pitfalls of genetic testing in Greece. Pers Med 2011;8:551-61.
12. Kricka LJ, Fortina P, Mai Y, Patrinos GP. Direct-to-consumer genetic testing: a view from Europe. Nat Rev Genet 2011;12: 670.
13. Rottenkolber D, Schmied, S, Rottenkolber M, Farker K, Salj é K, Mueller S, et al. Adverse drug reaction in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf 2011;20:626-34.
14. Stark R, John J, Leidl R. Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach. BMC Health Serv Res 2011;11:9.
15. Patrinos GP. General considerations for integrating pharmacogenomics into the mainstream medical practice. Hum Genomics 2010;4:371-4.